samedan logo
 
 
spacer
home > pmps > summer 2019 > serialising drugs to combat fraud
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Serialising Drugs to Combat Fraud

The worldwide pharmaceutical market is huge, estimated at over $1 trillion in 2016 (1). A growing portion of this is over-the-counter (OTC) medicines, which are projected to be worth $178 billion in 2024, driven by governments encouraging our ageing populations to check with their pharmacist before going to A&E to reduce the non-urgent load on hospitals (2).

An increasing number of patients are purchasing these OTC products online. Euromonitor estimates that despite only being 2% of sales in 2017, the speed at which this has grown in recent years has focused pharma companies’ attention, especially after Amazon quietly launched a line of OTC products in 2018 (3-4).

Unfortunately, buying pharmaceutical products online is fraught with issues; for example, it is estimated that a significant proportion of Viagra bought online is fake, and the side effects of counterfeit drugs can be fatal (5-6). Recently, the UK authorities seized a large amount of Diazepam, modafinil, and dermal fillers (7). The effect of poor dermal products can be life changing (8).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gillian Ewers is an experienced marketing professional with a track record of launching new products to market in hightech businesses. She brings a wealth of knowledge of delivering strategic roadmaps, marketing materials, and product lifecycle management across multiple sectors, including semiconductors and digital inkjet printing, at companies such as Texas Instruments, Dialog, CSR, and Xaar.
spacer
Gillian Ewers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

October 5th, 2021 – SCHLIEREN, (Zurich, Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement